Nadroparin calcium: a review of its basic and clinical pharmacology
Objective: To evaluate critically the evidence on the basic and clinical pharmacology of nadroparin calcium. Data source: We conducted a literature review from October 1985 to September 2010 in the electronic databases: Pubmed, Cochrane, MD Cosult, Medscape, Scielo and Instituto Nacional de Vigilanc...
| Autor Principal: | Ospina-González, Diego Alexander; Universidad de los Andes |
|---|---|
| Otros Autores: | Martínez, Jairo Andrés; Universidad de los Andes, Cifuentes, Luis Fernando; Universidad de los Andes |
| Formato: | info:eu-repo/semantics/article |
| Idioma: | spa |
| Publicado: |
Pontificia Universidad Javeriana
2011
|
| Materias: | |
| Acceso en línea: |
http://revistas.javeriana.edu.co/index.php/vnimedica/article/view/16106 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: |
Objective: To evaluate critically the evidence on the basic and clinical pharmacology of nadroparin calcium. Data source: We conducted a literature review from October 1985 to September 2010 in the electronic databases: Pubmed, Cochrane, MD Cosult, Medscape, Scielo and Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA).Study selection: Studies published in English, Spanish or French made in humans and animals for experimentation which reviewed the basic and clinical pharmacology of nadroparin calcium were included.Data extraction and synthesis: 792 abstracts were reviewed by authors and 60 papers were selected that met inclusion criteria according to a standardized method All discrepancies were resolvedby discussion and consensus. Conclusion: Some studies have shown that the efficacy of nadroparin calcium is equal or superior to unfractionated heparin (UFH) and placebo, however, the strength of assessed evidence has been insufficient for considering nadroparin calcium superior to other low molecular weight heparins (LMWH). Literature shows that LMWHs therapy is more cost-effective and safer than UFH therapy in general. It does not exist enough, strong and conclusive evidence for considering antithrombotic nadroparin calcium therapy greater to other LMWHs. LMWHs have shown a significant reduction in tumor angiogenesis and increased survival in oncology patients. To conduct further research is necessary to characterize and understand better this new finding. |
|---|